TScan Therapeutics (TCRX) Profit After Tax (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Profit After Tax data on file, last reported at -$28.7 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 16.0% year-over-year to -$28.7 million in Q1 2026; TTM through Mar 2026 was -$124.3 million, a 5.43% increase from a year earlier, with the FY2025 full-year figure at -$129.8 million, down 1.8% from the prior year.
• Profit After Tax for Q1 2026 stood at -$28.7 million, down from -$23.0 million in the prior quarter.
• Over the last five years, Profit After Tax for TCRX reached as high as -$15.1 million in Q2 2022 and fell as low as -$37.0 million in Q2 2025.
• Historically, Profit After Tax has averaged -$26.0 million across 5 years, with a median of -$24.0 million in 2023.
• Across the five-year window, Profit After Tax sank 104.75% in 2022 and surged 35.74% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$18.7 million in 2022, then dropped by 4.9% to -$19.6 million in 2023, then tumbled by 82.54% to -$35.8 million in 2024, then jumped by 35.74% to -$23.0 million in 2025, then fell by 24.58% to -$28.7 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$28.7 million in Q1 2026, -$23.0 million in Q4 2025, and -$35.7 million in Q3 2025.